IANB: Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis

Sponsor
Armed Forces Institute of Dentistry, Pakistan (Other)
Overall Status
Recruiting
CT.gov ID
NCT05840913
Collaborator
(none)
78
2
2
6
39
6.5

Study Details

Study Description

Brief Summary

This is a randomized clinical trial comparing the anaesthetic efficacy of 1.8 and 3.6 mL of Articaine for inferior alveolar nerve block when treating mandibular molars with Irreversible Pulpitis

Condition or Disease Intervention/Treatment Phase
  • Drug: Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
Phase 2

Detailed Description

An informed written consent of the patients will be obtained. (Annex-A).

Demographic details (including name, age, gender, contact) will be obtained on data collection forms. (Annex-B).

The principal investigator will perform the local anesthetic injection and the participants will be assigned to one of the groups.

Group 1: 1.8 mL articaine Group 2: 3.6 mL articaine

Before starting the treatment i.e. before administration of the anesthetic solution, each participant will receive an explanation regarding the Heft-Parker visual analog pain scale (VAS) and asked to rate their pain on a self-report questionnaire.

A topical anesthetic gel (20% Benzocaine; Premier, Philadelphia, PA) will passively placed at the injection site with a cotton tip applicator for 1 minute before injection.

A conventional IANB will administered using an aspirating syringe with a side-loading cartridge system (Dena Instruments; Forgeman Instruments Co, Sialkot, Pakistan) and a 27-G 31-mm needle (C-K ject; CK Dental, Kor-Kyungji-do, Korea).

All injections will be given by one clinician in both groups. Group 2 participants will receive 2 cartridges of the anesthetic solution and group 1 will receive a cartridge of the anesthetic solution followed by a mock injection.

The rest of the procedure will be performed by a second investigator. Ten minutes after injection, the participants will be asked whether they have lip numbness. Any patient without lip numbness at this stage will excluded from study.

Fifteen minutes after the administration of the IANB, the teeth will be re-evaluated with electric pulp testing. On positive response, participants will be again asked to rate their pain using the HP VAS on the questionnaire.

If higher than mild pain is reported, supplemental anesthesia (intraperiodontal ligament or intrapulpal injection) will be used to provide patient comfort throughout the treatment.

Then teeth under study will be isolated with a rubber dam, and caries removed followed by the preparation of an endodontic access cavity. The participants will be informed to stop the practitioner at any stage of treatment if they feel more than mild pain by raising their hand.

At the end of each stage of treatment (access cavity preparation, pulp chamber opening, root canal instrumentation), the practitioner will stop work and ask the participants to rate their pain if they do not raise their hand during treatment.

The success will be defined as the ability to undertake pulp access and canal instrumentation with no or mild pain (Heft-Parker visual analog scale [HP VAS] score <55 mm) whereas moderate or severe pain will considered as failure of anesthesia.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
78 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Comparison of Anaesthetic Effectiveness of Different Volumes of Articaine for Inferior Alveolar Nerve Block in Molar Teeth With Symptomatic Irreversible Pulpitis
Anticipated Study Start Date :
Apr 30, 2023
Anticipated Primary Completion Date :
Oct 30, 2023
Anticipated Study Completion Date :
Oct 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1.8 ml group

Participants in this group will be given 1 cartridge of articaine solution pre-operatively to endodontic treatment

Drug: Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
Local anesthetic injection for intra- operative pain control
Other Names:
  • Orabloc 4% Articaine 1:100,000 1.8 ml
  • Experimental: 3.6 ml group

    Participants in this group will be given 2 cartridges of articaine solution pre-operatively to endodontic treatment

    Drug: Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge
    Local anesthetic injection for intra- operative pain control
    Other Names:
  • Orabloc 4% Articaine 1:100,000 1.8 ml
  • Outcome Measures

    Primary Outcome Measures

    1. Pain Control [30 to 45 minutes]

      Pain recordings on a self-report questionnaire using Heft-Parker Visual Analogue Scale. The scores are divided into 4 categories: No pain 0 mm Mild pain > 0 mm and ≤ 54 mm Moderate pain > 54 mm and < 114 mm Severe Pain ≥ 114 mm The success will be defined as the ability to undertake pulp access and canal instrumentation with no or mild pain (Heft-Parker visual analog scale [HP VAS] score <55 mm) whereas moderate or severe pain will considered as failure of anesthesia.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Healthy patients, including age group 18-55 years old

    • Mandibular first molar tooth with symptomatic irreversible pulpitis

    • Normal periapical radiographic appearance

    • Moderate pain on Heft-Parker VAS ( > 54 mm and < 114 mm )

    • Lingering pain or prolonged response to the cold testing (more than 10 seconds)

    • Positive response to electric pulp testing

    Exclusion Criteria:
    • Patients who have taken analgesic or anti-inflammatory drugs within 6 hours before treatment visit

    • History of allergy to 4% articaine or epinephrine

    • Patients with systemic diseases

    • Pregnant or lactating patients

    • Teeth with severe periodontal disease

    • Teeth with periapical radiolucency

    • Any type of medication that could potentially interact with the anesthetic solution (antihypertensives)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Armed Forces Institue Of Dentistry Rawalpindi Punjab Pakistan 46000
    2 Armed Forces Institute of Dentistry Rawalpindi Punjab Pakistan 46000

    Sponsors and Collaborators

    • Armed Forces Institute of Dentistry, Pakistan

    Investigators

    • Principal Investigator: Kanza Zafar, BDS, AFID

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kanza Zafar, Dr. Kanza Zafar, Principal Investigator and Resident Operative Dentistry and Endodontics, Armed Forces Institute of Dentistry, Pakistan
    ClinicalTrials.gov Identifier:
    NCT05840913
    Other Study ID Numbers:
    • Articaine Efficacy for IANB
    First Posted:
    May 3, 2023
    Last Update Posted:
    May 3, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 3, 2023